Anteris Technologies Ltd (AVR.XA)
| Previous close | 11.99 |
| Open | 11.53 |
| Bid | 11.84 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 11.34 - 11.94 |
| 52-week range | 9.36 - 23.60 |
| Volume | |
| Avg. volume | 3,926 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Anteris Submits Confidential Draft Registration Statement for Proposed US IPO
BRISBANE, Australia & EAGAN, Minn., August 13, 2024--Anteris Technologies Ltd ("Anteris") (ASX: AVR) has submitted a confidential draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") by its affiliate, Anteris Technologies Global Corp. ("Anteris Global"), relating to the proposed U.S. initial public offering by Anteris Global of its shares of common stock (the "Proposed Offering").
- Business Wire
Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip™ Passes Animal Study
BRISBANE, Australia & EAGAN, Minn., July 01, 2024--Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of TAVR and the world’s only balloon-expandable, single-piece biomimetic aortic replacement valve shaped to mimic the native human valve, and v2vmedtech, inc., a structural heart company developing a next generation Transcatheter Edge to Edge Repair (TEER) system for mitral and tricuspid valve regurgitation today announced they have reached concep
- Business Wire
Anteris Provides Update on DurAVR™ THV Valve-in-Valve Experience Presented at New York Valves 2024
BRISBANE, Australia & EAGAN, Minn., June 13, 2024--Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of TAVR and the world’s only balloon-expandable, single-piece biomimetic aortic replacement valve shaped to mimic the native human valve, today announced a summation of the Company’s presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City.
